Rating Action:
Moody's assigns Caa1 to Valeant's unsecured notes; outlook stable
17 May 2018
New York, May 17, 2018 -- Moody's Investors Service ("Moody's") assigned a Caa1 rating to the new senior unsecured note issuance of Valeant Pharmaceuticals International, guaranteed by Valeant Pharmaceuticals International, Inc. (collectively "Valeant"). There are no changes to Valeant's other ratings including the B3 Corporate Family Rating, the B3-PD Probability of Default Rating, the Ba3 senior secured rating, Caa1 senior unsecured rating and SGL-2 Speculative Grade Liquidity Rating. The outlook remains stable.
Proceeds of the notes, together with a term loan refinancing, will be used to repay existing term loans and senior notes in a leverage-neutral refinancing. The transaction is credit positive because it will extend Valeant's debt maturities and modestly reduce total interest costs.
Ratings assigned:
Valeant Pharmaceuticals International, guaranteed by Valeant Pharmaceuticals International, Inc.:
Backed senior unsecured notes due 2027, at Caa1 (LGD4)